JD5037

Known as: JD-5037 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2016
0120122016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Cannabinoid receptor 1 (CB1R) antagonists have been proven to be effective anti-obesity drugs; however, psychiatric side effects… (More)
Is this relevant?
2017
2017
OBJECTIVE In visceral obesity, an overactive endocannabinoid/CB1 receptor (CB1R) system promotes increased caloric intake and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
JD5037 (1) is a potent and selective, peripherally acting inverse agonist of the cannabinoid (CB1 R) receptor. Peripheral CB1… (More)
Is this relevant?
Review
2017
Review
2017
Despite the enormous public health problem caused by obesity and its metabolic complications, available treatments are limited… (More)
Is this relevant?
2016
2016
Therapeutics aimed at blocking the cannabinoid 1 (CB1) receptor for treatment of obesity resulted in significant improvements in… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2015
2015
UNLABELLED Hepatocellular carcinoma (HCC) has high mortality and no adequate treatment. Endocannabinoids interact with hepatic… (More)
Is this relevant?
2014
2014
UNLABELLED Obesity is associated with increased activity of two lipid signaling systems (endocannabinoids [ECs] and ceramides… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2013
Review
2013
Antagonists (inverse agonists) of the cannabinoid-1 (CB1) receptor showed promise as new therapies for controlling obesity and… (More)
Is this relevant?
2012
2012
Analogs of SLV-319 (Ibipinibant), a CB1 receptor inverse agonist, were synthesized with functionality intended to limit brain… (More)
Is this relevant?